Cytomegalovirus Infection

Home
Solutions
Infectious Diseases
Viral Infections
Cytomegalovirus Infection

Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Cytomegalovirus Infection

Cytomegalovirus (CMV) is a widely infectious betaherpesvirus which causes great health burden especially to immunocompromised, organ transplant recipients and congenitally infected infants. At our company, we specialize in the development of cutting-edge vaccines and therapies for CMV infection.

Introduction to Cytomegalovirus Infection

The cytomegalovirus (CMV) infection is quite concerning as a public health problem especially in the case of newborns and immunocompromised individuals. CMV is the most common virus that gets transmitted in utero. It is a member of the herpes virus family and congenital infection in infants potentially poses a significant risk of severe neurological deficits and other serious health problems. In the US, congenital CMV affects 0.5% to 0.7% of all pregnancies which results in now only symptomatic cases and disabilities but also sensorineural hearing loss and cognitive developmental delays.

Example of single-cell transcriptome data analysis of HCMV-infected macrophages. Fig.1 Single-cell transcriptome analysis of HCMV-infected macrophages. (Schwartz M., et al., 2023)

Vaccine Development for Cytomegalovirus Infection

Subunit Vaccines

The CMV glycoprotein B (gB) subunit vaccines have been successful at a clinical trial level since they incorporate viral proteins that can trigger an immune response and boost one's recombinant technology. Furthermore, MF59 adjuvants have also been key at increasing the efficacy of such vaccines which was seen in phase II trials.

Nucleic acid Vaccines

Plasmid DNA and self-amplifying RNA vaccines, in particular, sand nucleic acid vaccines, precisely induce cellular immune response and humoral as well. These vaccines contain genetic blueprints encoding CMV antigens which prompts the host cells to express viral proteins resulting in immune response for elicitation.

Vectored Vaccines

Vectored vaccines employ viral vectors like modified vaccinia virus Ankara (MVA) or alphavirus replicon particles as carriers for CMV antigens. These vaccines display strong capability of stimulating long lasting cellular and humoral responses which prompted some candidates to enter phase I and II clinical trials.

Live Attenuated and DISC Vaccines

Willingly weakened vaccines including the Towne strain alongside the impaired infectious single cycle (DISC) vaccines such as the V160 candidate have been noted to have the capacity to imitate natural immunity. These forms of the vaccine will be able to replicate only to a high extent and in turn will be able to invoke a wide-ranging immune response without any causal disease.

Therapeutics Development for Cytomegalovirus Infection

Antibiotic Therapy

Strategies have been devised for the development of antiviral drugs for CMV through the inhibition of certain viral enzymes while also targeting the replicative and entry stages.

Nucleoside Analogs

Ganciclovir and its prodrug valganciclovir have been the hallmark of CMV therapy for years. They are nucleoside analogs blocking the CMV DNA polymerase and are proven to be effective in both prophylaxis and therapeutics.

Non-Nucleoside Inhibitors

Non-nucleoside inhibitors including maribavir and letermovir interferes with the mechanisms of viral replication by ensuring UL97 Kinase and the terminase complex are efficiently utilized.

Our Services

We lead the advance within CMV vaccine and therapy development owing to our scientific research which we put into practice to create innovative solutions to the issue posed by Cytomegalovirus (CMV).

Diagnostics Development

Disease Models

Rhesus Macaque CMV (RhCMV) Models
Guinea Pig CMV (GPCMV) Modes
Murine CMV (mCMV) Models
Humanized Mouse Models
NHP (Non-Human Primate) Models

Vaccine Development

Therapeutic Development

Preclinical research is a cornerstone of our development pipeline. We conduct rigorous in vitro and in vivo studies to evaluate the safety and efficacy of vaccine and drug candidates. If you are interested in our services, please feel free to contact us.

References

Schwartz, Michal, et al. "Molecular characterization of human cytomegalovirus infection with single-cell transcriptomics." Nature microbiology 8.3 (2023): 455-468.
Britt, William J., and Mark N. Prichard. "New therapies for human cytomegalovirus infections." Antiviral research 159 (2018): 153-174.
Anderholm, K. M., Craig J. Bierle, and Mark R. Schleiss. "Cytomegalovirus vaccines: current status and future prospects." Drugs 76 (2016): 1625-1645.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy